Insider Selling: Genomic Health (NASDAQ:GHDX) COO Sells $164,000.00 in Stock

Genomic Health (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of the business’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $32.80, for a total transaction of $164,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

G Bradley Cole also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Tuesday, February 20th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $32.89, for a total transaction of $164,450.00.
  • On Tuesday, January 9th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $35.51, for a total transaction of $177,550.00.

GHDX stock opened at $30.93 on Friday. Genomic Health has a fifty-two week low of $26.54 and a fifty-two week high of $37.50.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings results on Thursday, March 8th. The medical research company reported $0.08 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by ($0.01). The business had revenue of $87.50 million during the quarter, compared to analyst estimates of $88.96 million. Genomic Health had a negative net margin of 1.13% and a negative return on equity of 0.83%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period last year, the company earned $0.04 earnings per share. analysts expect that Genomic Health will post 0.43 earnings per share for the current year.

A number of brokerages have issued reports on GHDX. BidaskClub upgraded shares of Genomic Health from a “hold” rating to a “buy” rating in a research note on Friday, March 30th. Zacks Investment Research lowered shares of Genomic Health from a “hold” rating to a “strong sell” rating in a research note on Friday, March 9th. Piper Jaffray restated a “hold” rating and set a $33.00 target price on shares of Genomic Health in a research note on Thursday, March 8th. ValuEngine lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st. Finally, Canaccord Genuity restated a “buy” rating and set a $42.00 target price on shares of Genomic Health in a research note on Tuesday, January 16th. Four equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. Genomic Health presently has an average rating of “Hold” and a consensus price target of $32.67.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC boosted its holdings in Genomic Health by 16.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,012,000 shares of the medical research company’s stock valued at $34,610,000 after purchasing an additional 141,300 shares in the last quarter. State Street Corp boosted its holdings in Genomic Health by 2.5% in the second quarter. State Street Corp now owns 517,313 shares of the medical research company’s stock valued at $16,840,000 after purchasing an additional 12,696 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Genomic Health by 1.2% in the third quarter. Schwab Charles Investment Management Inc. now owns 503,244 shares of the medical research company’s stock valued at $16,150,000 after purchasing an additional 5,904 shares in the last quarter. State Farm Mutual Automobile Insurance Co. boosted its holdings in Genomic Health by 10.6% in the fourth quarter. State Farm Mutual Automobile Insurance Co. now owns 350,741 shares of the medical research company’s stock valued at $11,995,000 after purchasing an additional 33,501 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in Genomic Health by 9.1% in the fourth quarter. American Century Companies Inc. now owns 194,503 shares of the medical research company’s stock valued at $6,652,000 after purchasing an additional 16,217 shares in the last quarter. 89.99% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Insider Selling: Genomic Health (NASDAQ:GHDX) COO Sells $164,000.00 in Stock” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/genomic-health-inc-ghdx-coo-g-bradley-cole-sells-5000-shares-of-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply